Delivery Order SPE2DB20D1100-SPE2DB25FD7E6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors, valued at $43,477.39 with a firm fixed price structure. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency (DLA) awarded a $5,128.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on September 9, 2025, with completion scheduled for September 10, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. The award represents a child contract under AmerisourceBergen's substantial $1...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a $53,153.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 14, 2025, with completion targeted for July 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively procured...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $88,802.19 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $44,168.03 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on May 30, 2025, with completion scheduled for June 2, 2025. This delivery order represents a non-competitive, non-set-aside award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The IDC, valued at $999,999,999 and running through December 2026, serves as a...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at approximately $42,601.58 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion on June 20, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD7E6Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical supply agreement running through December 2026 that serves as the primary vehicle for global pharmaceutical support to military healthcare programs. AmerisourceBergen Drug Corp, one of the nation's leading pharmaceutical distributors, maintains an extensive portfolio of federal medical supply contracts with the DLA and Defense Health Agency. The company supplies a comprehensive range of pharmaceutical products and medical commodities across multiple therapeutic domains to support military and veteran healthcare systems. Dupixent, a biologic medication used to treat moderate-to-severe atopic dermatitis and other inflammatory conditions, represents one of many specialty medications within the company's federal procurement portfolio. This delivery order demonstrates AmerisourceBergen's continued role as a critical vendor in the military medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 7/30/25 |